Shilpa Medicare Ltd (SHILPAMED) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Shilpa Medicare reported its highest ever quarterly EBITDA.
- The company maintains a strong focus on asset monetization.
- Q1 FY26 marked the highest ever Q1 performance for the API business segment.
- Shilpa received marketing authorization for Nor-Ursodeoxycholic acid (NorUDCA), its first internally developed NCE.
- The company received an EIR from the US FDA for its transdermal patch manufacturing facility.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.